Illumina Inc. Licences ReaMetrix to Codevelop Molecular Diagnostic Panels.
Illumina Inc. and ReaMetrix Inc. announced the formation of a diagnostic collaboration under which the companies plan to codevelop molecular diagnostic panels for a range of disease areas. Under the terms of the agreement, ReaMetrix will gain nonexclusive rights to market the resulting panels to the country of India and its more than 1 billion inhabitants. Illumina will retain rights to market the tests outside of India. Illumina will supply VeraCode technology and other reagents for the tests. ReaMetrix will develop, validate, and market diagnostic panels based on Illumina's upcoming BeadXpress platform, scheduled for market introduction before the end of the calendar year.
